Ann: Appendix 4C - quarterly, page-6

Please remember the rest of the world is up Covid creek.

I think the NZ sales are really important. First, its a country with no COVID getting in the way of the medical system. Second, you need to compare these oncosil sales to the rate of newly diagnosed LAPC in NZ. I think 2 in a quarter would be a high %. Third, there's no state reimbursement for oncosil in NZ (I think) as yet. Fourth, it shows that if clinicians become committed they will actually use it in preference to standard radiotherapy. I suspect the clinicians dealing with LAPC are a closer knit group in NZ which could help referral/uptake.

If that's replicated in other COVID normal markets it augers well.

Please - don;t lets complain about actual sales.

As for Osprey - watch out for the NZ group publishing their own experience first. Early adopters also want the kudos of publications and presentations. And that creates more evidence as well as momentum.